Imaging and blood markers to predict spread of soft-tissue sarcoma
Tests whether imaging and blood markers can predict spread in adults with soft-tissue sarcoma.
Plain-language title generated from the registry record
Registry title: IVIM & OLINK in Sarcoma
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a grade 2 or 3 soft tissue sarcoma larger than 5 cm (2 in). It studies scan and blood markers that may predict spread of the cancer.
- Age
- 18 Years to 100 Years
- Sex
- All sexes can join.
- Disease stage
- Grade 2 or 3 soft tissue sarcoma, greater than 5 cm (2 in) in largest dimension.
Main reasons for not taking part
- Cannot have an MRI scan, as per the institution's current guidelines (for patients who need an MRI)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05950594, who can take part
Where in Canada
- University Health NetworkToronto, CanadaContact: David Shultz, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT05950594
- Record updated
- 16 March 2026
- Original description
The hypoxia > metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).Read full original descriptionShow less
Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas
The hypoxia > metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Inclusion: Age ≥ 18 years; Ability to understand and the willingness to sign a written informed consent document; Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension.
Exclusion: Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI).